231 related articles for article (PubMed ID: 34864331)
21. Discovery of novel PARP/PI3K dual inhibitors with high efficiency against BRCA-proficient triple negative breast cancer.
Wang J; He G; Li H; Ge Y; Wang S; Xu Y; Zhu Q
Eur J Med Chem; 2021 Mar; 213():113054. PubMed ID: 33309164
[TBL] [Abstract][Full Text] [Related]
22. Characterization of human cyclin-dependent kinase 12 (CDK12) and CDK13 complexes in C-terminal domain phosphorylation, gene transcription, and RNA processing.
Liang K; Gao X; Gilmore JM; Florens L; Washburn MP; Smith E; Shilatifard A
Mol Cell Biol; 2015 Mar; 35(6):928-38. PubMed ID: 25561469
[TBL] [Abstract][Full Text] [Related]
23. Induction of BRCAness in Triple-Negative Breast Cancer by a CDK12/13 Inhibitor Improves Chemotherapy.
Hopkins JL; Zou L
Cancer Cell; 2019 Nov; 36(5):461-463. PubMed ID: 31715127
[TBL] [Abstract][Full Text] [Related]
24. Rational Design and Synthesis of Novel Dual PROTACs for Simultaneous Degradation of EGFR and PARP.
Zheng M; Huo J; Gu X; Wang Y; Wu C; Zhang Q; Wang W; Liu Y; Liu Y; Zhou X; Chen L; Zhou Y; Li H
J Med Chem; 2021 Jun; 64(11):7839-7852. PubMed ID: 34038131
[TBL] [Abstract][Full Text] [Related]
25. Th e role of CDK12 in tumor bio logy.
Dzimková M; Procházková J; Klát J; Kohoutek J
Klin Onkol; 2020; 33(4):260-267. PubMed ID: 32894954
[TBL] [Abstract][Full Text] [Related]
26. CDK13/CDC2L5 interacts with L-type cyclins and regulates alternative splicing.
Chen HH; Wong YH; Geneviere AM; Fann MJ
Biochem Biophys Res Commun; 2007 Mar; 354(3):735-40. PubMed ID: 17261272
[TBL] [Abstract][Full Text] [Related]
27. AR-A014418 regulates intronic polyadenylation and transcription of PD-L1 through inhibiting CDK12 and CDK13 in tumor cells.
Zhang G; Lan B; Zhang X; Lin M; Liu Y; Chen J; Guo F
J Immunother Cancer; 2023 May; 11(5):. PubMed ID: 37164450
[TBL] [Abstract][Full Text] [Related]
28. Selective degradation of PARP2 by PROTACs via recruiting DCAF16 for triple-negative breast cancer.
Pu C; Tong Y; Liu Y; Lan S; Wang S; Yan G; Zhang H; Luo D; Ma X; Yu S; Huang Q; Deng R; Li R
Eur J Med Chem; 2022 Jun; 236():114321. PubMed ID: 35430559
[TBL] [Abstract][Full Text] [Related]
29. CDK12: an emerging therapeutic target for cancer.
Lui GYL; Grandori C; Kemp CJ
J Clin Pathol; 2018 Nov; 71(11):957-962. PubMed ID: 30104286
[TBL] [Abstract][Full Text] [Related]
30. Degradation of CCNK/CDK12 is a druggable vulnerability of colorectal cancer.
Dieter SM; Siegl C; Codó PL; Huerta M; Ostermann-Parucha AL; Schulz E; Zowada MK; Martin S; Laaber K; Nowrouzi A; Blatter M; Kreth S; Westermann F; Benner A; Uhrig U; Putzker K; Lewis J; Haegebarth A; Mumberg D; Holton SJ; Weiske J; Toepper LM; Scheib U; Siemeister G; Ball CR; Kuster B; Stoehr G; Hahne H; Johannes S; Lange M; Herbst F; Glimm H
Cell Rep; 2021 Jul; 36(3):109394. PubMed ID: 34289372
[TBL] [Abstract][Full Text] [Related]
31. Design and Synthesis of Poly(ADP-ribose) Polymerase Inhibitors: Impact of Adenosine Pocket-Binding Motif Appendage to the 3-Oxo-2,3-dihydrobenzofuran-7-carboxamide on Potency and Selectivity.
Velagapudi UK; Langelier MF; Delgado-Martin C; Diolaiti ME; Bakker S; Ashworth A; Patel BA; Shao X; Pascal JM; Talele TT
J Med Chem; 2019 Jun; 62(11):5330-5357. PubMed ID: 31042381
[TBL] [Abstract][Full Text] [Related]
32. Design, synthesis and anticancer activities of novel dual poly(ADP-ribose) polymerase-1/histone deacetylase-1 inhibitors.
Tian Y; Xie Z; Liao C
Bioorg Med Chem Lett; 2020 Apr; 30(8):127036. PubMed ID: 32088129
[TBL] [Abstract][Full Text] [Related]
33. Current progress and novel strategies that target CDK12 for drug discovery.
Lei P; Zhang J; Liao P; Ren C; Wang J; Wang Y
Eur J Med Chem; 2022 Oct; 240():114603. PubMed ID: 35868123
[TBL] [Abstract][Full Text] [Related]
34. Systematic Characterization of Recurrent Genomic Alterations in Cyclin-Dependent Kinases Reveals Potential Therapeutic Strategies for Cancer Treatment.
Shan W; Yuan J; Hu Z; Jiang J; Wang Y; Loo N; Fan L; Tang Z; Zhang T; Xu M; Pan Y; Lu J; Long M; Tanyi JL; Montone KT; Fan Y; Hu X; Zhang Y; Zhang L
Cell Rep; 2020 Jul; 32(2):107884. PubMed ID: 32668240
[TBL] [Abstract][Full Text] [Related]
35. Structure-Based Design of Selective Noncovalent CDK12 Inhibitors.
Johannes JW; Denz CR; Su N; Wu A; Impastato AC; Mlynarski S; Varnes JG; Prince DB; Cidado J; Gao N; Haddrick M; Jones NH; Li S; Li X; Liu Y; Nguyen TB; O'Connell N; Rivers E; Robbins DW; Tomlinson R; Yao T; Zhu X; Ferguson AD; Lamb ML; Manchester JI; Guichard S
ChemMedChem; 2018 Feb; 13(3):231-235. PubMed ID: 29266803
[TBL] [Abstract][Full Text] [Related]
36. Effective degradation of EGFR
Qu X; Liu H; Song X; Sun N; Zhong H; Qiu X; Yang X; Jiang B
Eur J Med Chem; 2021 Jun; 218():113328. PubMed ID: 33773286
[TBL] [Abstract][Full Text] [Related]
37. Structure-based design, synthesis, and evaluation of inhibitors with high selectivity for PARP-1 over PARP-2.
Yu J; Luo L; Hu T; Cui Y; Sun X; Gou W; Hou W; Li Y; Sun T
Eur J Med Chem; 2022 Jan; 227():113898. PubMed ID: 34656898
[TBL] [Abstract][Full Text] [Related]
38. Development, validation, and evaluation of a deep learning model to screen cyclin-dependent kinase 12 inhibitors in cancers.
Wen T; Wang J; Lu R; Tan S; Li P; Yao X; Liu H; Yi Z; Li L; Liu S; Gao P; Qian H; Xie G; Ma F
Eur J Med Chem; 2023 Mar; 250():115199. PubMed ID: 36827953
[TBL] [Abstract][Full Text] [Related]
39. Kub5-Hera
Motea EA; Fattah FJ; Xiao L; Girard L; Rommel A; Morales JC; Patidar P; Zhou Y; Porter A; Xie Y; Minna JD; Boothman DA
Clin Cancer Res; 2018 Dec; 24(24):6459-6470. PubMed ID: 30108102
[TBL] [Abstract][Full Text] [Related]
40. Cyclin-Dependent Kinase Synthetic Lethality Partners in DNA Damage Response.
Kciuk M; Gielecińska A; Mujwar S; Mojzych M; Kontek R
Int J Mol Sci; 2022 Mar; 23(7):. PubMed ID: 35408915
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
